A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma
Ricardo Ahrens, Kyra Ahrens, Maximilian Al-Bazaz, Lisa Leypoldt, Carsten Bokemeyer, Winfried Alsdorf, Katja Weisel · 2026
Read A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma by Ricardo Ahrens, Kyra Ahrens, Maximilian Al-Bazaz, Lisa Leypoldt, Carsten Bokemeyer, Winfried Alsdorf, Katja Weisel (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13542101.txt.
Description
Ahrens and co-authors write to the editor with a plan for choosing the next drug when a myeloma patient's cancer escapes a targeted immunotherapy. The target, GPRC5D, is attacked by drug formats that grip parts of the receptor. At relapse, a mutation can mean two different things: the target may be gone, or changed at one grip point while other drugs can still hold. Telling those apart decides whether to stay in the drug class or leave it.
The team built a two-stage structural model for that call. The first stage judges whether a variant kills surface display of the receptor. The second scores how a displayed variant would disturb each drug's binding, using the structure of one approved drug bound to the target. The letter argues relapse care should move from target-based to mutation-based sequencing. The framework awaits clinical testing.
Catalog record
| CREATOR | Ricardo Ahrens, Kyra Ahrens, Maximilian Al-Bazaz, Lisa Leypoldt, Carsten Bokemeyer, Winfried Alsdorf, Katja Weisel |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |